Tenosynovial Giant Cell Tumor
📧 Sign up to get email alerts when something new happens for Tenosynovial Giant Cell Tumor.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-10-20FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) from Daiichi Sankyo Inc.
-
CLINICAL_TRIALS trial_result · 2021-08-31Clinical Trial Update: Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor [Phase 1, Phase 2]
Clinical trial update for cabiralizumab in pigmented villonodular synovitis and diffuse-type tenosynovial giant cell tumor; study completed …
-
FDA approval · 2020-12-16FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc. This action pertains t…
-
FDA approval · 2020-08-04FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc.
-
FDA approval · 2020-04-17FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) from Daiichi Sankyo Inc., expanding the regulatory status f…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-04-10FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approves a supplemental application for TURALIO (PEXIDARTINIB HYDROCHLORIDE) from Daiichi Sankyo Inc.
-
CLINICAL_TRIALS trial_result · 2020-01-10Clinical Trial Update: Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) [Phase 3]
Phase 3 trial of pexidartinib in pigmented villonodular synovitis and related tenosynovial giant cell tumors completed with posted results.
-
FDA approval · 2019-11-19FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc., updating the drug's l…
-
FDA approval · 2019-08-02FDA Approved: TURALIO — Original Application (Daiichi Sankyo Inc.)
The FDA approved TURALIO (pexidartinib hydrochloride) in support of the original NDA for the treatment of tenosynovial giant cell tumor (TGC…
-
CLINICAL_TRIALS trial_result · 2013-04-16Clinical Trial Update: Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) [Phase 2]
Phase 2 trial assessing the efficacy of nilotinib in pigmented villonodular synovitis and tenosynovial giant cell tumor; the study status is…